Guangzhou Pharmaceutical Group plans to acquire a controlling stake in DaAn Gene with the intention of strengthening its diagnostic instrument business.

Reporters learned from the Guangzhou Pharmaceutical Group that recently, Guangzhou Pharmaceutical Group's wholly-owned subsidiary, Guangzhou Pharmaceutical Capital, signed formal transaction documents with Guangzhou Jinkong, Guangzhou Health Investment, and Guangyong Technology, shareholders of Daan Gene, including the "Agreement on the Acquisition of Controlling Equity of Guangzhou Daan Gene Co., Ltd." subject to certain conditions. According to the agreement, after the completion of this acquisition, Guangzhou Pharmaceutical Capital will become an indirect controlling shareholder of Daan Gene, with a total control of 373,736,601 shares, accounting for 26.63% of Daan Gene's total share capital. Guangzhou Pharmaceutical Group told reporters that controlling Daan Gene is a key layout for Guangzhou Pharmaceutical Group in the field of diagnostic instruments, which will help Guangzhou Pharmaceutical Group become a leader in the domestic in-vitro diagnostic field. At the same time, Daan Gene can also leverage Guangzhou Pharmaceutical Group's advantages in medicine distribution platform, research platform, etc., to make new breakthroughs in market promotion, new product development, and new technology research. Both parties have strategic synergy and broad cooperation prospects in the fields of medical devices, medical health services, elderly care, and general health.